# UCB Ventures

> UCB Ventures is a VC fund in Brussels backing Biotechnology and Health Care. See 21 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Brussels, Belgium
- Total investments: 21
- Last investment: Jun 2026
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/ucb-pharma/
- X (Twitter): https://twitter.com/ucb_news
- Website: https://www.ucbventures.com/
- Facebook: https://www.facebook.com/UCBBiopharma

UCB Ventures is a €150 million strategic corporate venture fund

## Contacts

5 contacts available for UCB Ventures. Shizune tracks 6 team members at UCB Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/ucb-ventures?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.8M–$3.5M |
| Series A | $6.6M–$75M |
| Series B | $9.4M–$135M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 57% |
| Health Care | 7 | 33% |
| Medical | 5 | 24% |
| Therapeutics | 5 | 24% |
| Life Science | 4 | 19% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 8 | 38% |
| Series B | 5 | 24% |
| Seed | 2 | 10% |
| Venture - Series Unknown | 2 | 10% |
| Series E | 1 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 43% |
| Belgium | 3 | 14% |
| Spain | 1 | 5% |
| United Kingdom | 1 | 5% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alicia Iruzun Lafitte | Partner | 4 | https://shizune.co/investors/profile/alicia-iruzun-lafitte |
| Emmanuel Lacroix | Partner | 1 | https://shizune.co/investors/profile/emmanuel-lacroix |
| Delphine Hajaji | Partner | 0 | https://shizune.co/investors/profile/delphine-hajaji |
| Erica Whittaker | Head of UCB Ventures | 9 | https://shizune.co/investors/profile/erica-whittaker |
| Joshua Sands | Principal | 0 | https://shizune.co/investors/profile/joshua-sands |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SonoThera | SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M | Series B | Jun 10, 2026 |  |
| Splice Bio | Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M | Series B | Jun 11, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M |  | Apr 03, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $102M | Series F | Apr 03, 2025 |  |
| Neurona Therapeutics | Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs. | $120M | Series E | Feb 08, 2024 |  |
| ViaNautis | Precision Solutions | $24.6M | Series A | Nov 13, 2023 |  |
| Switch Therapeutics | Switch Therapeutics is a biotech company that develops RNAi therapies based on technology. The company was founded in 2020 and is based in San Francisco, California, United States. | $52M | Series A | Mar 14, 2023 |  |
| Code Biotherapeutics | Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-basedgene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases. | $75M | Series A | Jun 07, 2022 |  |
| Splice Bio | Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $56.9M | Series A | Feb 16, 2022 |  |
| EsoBiotec | EsoBiotec is a Belgian biotechnology business focused on the discovery of novel cancer therapies.EsoBiotec's objective is to enable the human body to fight cancer by delivering 'in vivo' cell engineering to patients. | $3.5M | Seed | Sep 30, 2021 |  |

10 of 21 investments shown.

## Co-investors
- [Ysios Capital](https://shizune.co/investors/profile/ysios-capital) — VC Fund, 5 deals together
- [S.R.I.W.](https://shizune.co/investors/profile/s-r-i-w) — VC Fund, 4 deals together
- [The Column Group](https://shizune.co/investors/profile/the-column-group) — VC Fund, 4 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 3 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 3 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 3 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in Belgium](https://shizune.co/investors/biotechnology-vc-funds-belgium)
- [Biotech Investors in Belgium](https://shizune.co/investors/biotech-investors-belgium)
- [Biotech VC Funds in Belgium](https://shizune.co/investors/biotech-vc-funds-belgium)
- [Health Care Investors in Belgium](https://shizune.co/investors/health-care-investors-belgium)
- [Health Care VC Funds in Belgium](https://shizune.co/investors/health-care-vc-funds-belgium)
- [Medical VC Funds in Spain](https://shizune.co/investors/medical-vc-funds-spain)

## FAQ

### What does UCB Ventures invest in?

UCB Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is UCB Ventures's check size?

UCB Ventures typically joins rounds of $1.8M–$3.5M at Seed, $6.6M–$75M at Series A and $9.4M–$135M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds UCB Ventures participates in.

### How do I contact UCB Ventures?

Public channels for UCB Ventures include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at UCB Ventures?

The team at UCB Ventures includes Alicia Iruzun Lafitte (Partner), Emmanuel Lacroix (Partner) and Delphine Hajaji (Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co